Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 6/20 | 0.45 |
| ▸ | ATR | Q13535 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 3/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | METAP1 | P53582 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27874243 | 0.86 | MAPKAPK2 (0.39) | MAPKAPK2ATRLCKCYP17A1KMT2A | |
| SCHEMBL1350746 | 0.84 | MAPKAPK2 (0.42) | MAPKAPK2ATRLCKCYP17A1P2RX7 | |
| SCHEMBL30937577 | 0.83 | MAPKAPK2 (0.42) | MAPKAPK2ATRLCKCYP17A1P2RX7 | |
| SCHEMBL16839951 | 0.83 | MAPKAPK2 (0.41) | MAPKAPK2ATRLCKCYP17A1P2RX7 | |
| SCHEMBL23628484 | 0.82 | L3MBTL1 (0.41) | LMNAKMT2A | |
| SCHEMBL8074732 | 0.82 | ATR (0.48) | MAPKAPK2ATRLCKCYP17A1P2RX7 | |
| SCHEMBL30937609 | 0.82 | MAPKAPK2 (0.43) | MAPKAPK2ATRLCKCYP17A1P2RX7 | |
| Hydrochloric Acid SCHEMBL18668465 | 0.81 | L3MBTL1 (0.40) | LMNAKMT2A | |
| SCHEMBL6870765 | 0.81 | ATR (0.44) | MAPKAPK2ATRLCKCYP17A1P2RX7 | |
| SCHEMBL12133550 | 0.81 | LCK (0.46) | MAPKAPK2ATRLCKCYP17A1P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2391623-A1 | INHIBITORS OF AKT ACTIVITY | Merck Sharp & Dohme Corp. (US) | 2011-12-07 | — | — | EP | disclosed |
| US-20110288090-A1 | Inhibitors of AKT Activity | MERCK SHARP & DOHME CORP. | 2011-11-24 | — | — | US | disclosed |
| WO-2010088177-A1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME CORP. (US) | 2010-08-05 | — | — | WO | disclosed |
| WO-2010088177-A1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME CORP. (US) | 2010-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288090-A1 | Inhibitors of AKT Activity | PIK3CD, PIK3CA, PIK3CG | MAPKAPK2 172/4885ATR 714/4885LCK 190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.